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The Systolic Blood Pressure Intervention Trial (SPRINT) 
included a subset of 2,636 adults aged 75 years and older 
randomized to a systolic blood pressure (SBP) target 
of <120 mmHg or to <140 mmHg (1). Of the persons 
randomized to a SBP <120 mmHg, 33.4% were frail. Of 
the persons randomized to a SBP <140 mmHg, 28.4% 
were frail. The primary composite outcome of nonfatal 
myocardial infarction, acute coronary syndrome not 
resulting in a myocardial infarction, nonfatal stroke, nonfatal 
acute decompensated heart failure, and cardiovascular death 
was lowered 34% and all-cause mortality lowered 33% by a 
SBP <120 mmHg (1). These outcomes were not different in 
frail persons. These very elderly adults with a SBP <120 mmHg 
also had a 37% lowering of nonfatal heart failure and a 32% 
lowering of the primary outcome plus all-cause mortality (1). 
The absolute rate of serious adverse events was 2.4% in the 
lower SBP treatment group versus 1.4% in the standard 
SBP treatment group. Orthostatic hypotension occurred in 
21.0% in the lower SBP treatment group versus 21.8% in 
the standard SBP treatment group (1). This study did not 
include persons living in a nursing home or persons with 
diabetes, prior stroke, symptomatic heart failure, or a left 
ventricular ejection fraction (LVEF) <35% (1). 
The American College of Cardiology (ACC)/American 
Heart Association (AHA) 2017 guidelines will have to 
answer by expert medical opinion many questions not 
answered by SPRINT. What should the SBP goal and 
the diastolic blood pressure (DBP) goal be in adults with 
diabetes, an acute coronary syndrome, prior stroke or 
transient ischemic attack, heart failure with a preserved 
or low LVEF, a LVEF below 35%, younger than 50 years, 
at low-risk for cardiovascular events, or those living in a 
nursing home? The 2015 AHA/ACC/American Society 
of Hypertension scientific statement on treatment of 
hypertension in patients with coronary artery disease 
recommends a blood pressure (BP) goal of <140/90 mmHg 
in adults with stable angina, an acute coronary syndrome, 
and heart failure but states that a BP goal of <130/80 mmHg 
may be appropriate , especially in those with a prior 
myocardial infarction or stroke or at high risk for developing 
either (2). 
The DBP should not be lowered to <60 mmHg in 
any adult with coronary artery disease with myocardial 
ischemia, diabetes, or age older than 60 years of age (3,4). 
The SBP should not be lowered to <110 mmHg in these 
adults (3). Cardiovascular risk should be assessed to guide 
the diagnosis and therapy of hypertension (5). Although 
many hypertension experts recommend treating patients 
with cardiovascular risk factors with hypertension to a BP 
goal of <120/80 mmHg (6), not all recommend this goal (7). 
Hypertension in high-risk adults could be defined as a 
BP ≥130/80 mmHg with a threshold of treatment of 
130/80 mmHg with a goal SBP of < 120 mmHg (8). 
The Orthostatic Hypotension in Diabetics in the Action 
to Control Cardiovascular Risk in Diabetes Blood Pressure 
(ACCORD BP) trial investigated the prevalence, incidence, 
and prognostic significance of orthostatic hypotension in 
the ACCORD BP trial (9,10). The participants in this trial 
were at high risk for having orthostatic hypotension because 
they had type 2 diabetes, had hypertension, and were 
treated with antihypertensive drugs. The persons in this 
trial were a randomized to treatment with antihypertensive 
drugs to lower the SBP to <120 mmHg or to <140 mmHg. 
After 1 year, the SBP was 119.3 mmHg with intensive 
blood pressure control versus 133.5 mmHg with standard 
antihypertensive drug treatment (9). 
At 4 years, the prevalence of orthostatic hypotension was 
12.2% in hypertensive diabetics treated to a SBP <120 mmHg 
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versus 13.5% in hypertensive diabetics treated to a 
SBP <140 mmHg (9). At 4 years, the incidence of 
orthostatic hypotension was 9.9% in hypertensive diabetics 
treated to a SBP <120 mmHg versus 11.0% in hypertensive 
diabetics treated to a SBP <140 mmHg (9). Orthostatic 
hypotension was associated with a 62% increase in all-cause 
mortality and with a 85% increase in heart failure death or 
hospitalization (9).
A randomized clinical trial using a similar number 
of participants and design used in SPRINT needs to be 
performed in older hypertensive diabetics to investigate 
whether the SBP  goal should be <120 or <140 mmHg 
in hypertensive diabetics (10). The Orthostatic Hypotension 
in ACCORD BP study reassures us that hypertensive 
diabetics treated to a SBP goal of <120 mmHg will not have 
a higher prevalence or incidence of orthostatic hypotension 
than hypertensive diabetics treated to a SBP  goal of <140 
mmHg (9,10).
A meta-analysis of 19 randomized antihypertensive drug 
trials with 44,989 participants demonstrated that persons 
treated with more intensive BP lowering treatment had a 
mean BP of 133/76 mmHg compared to 140/81 mmHg 
with less intensive BP treatment group (11). At 3.8-year 
mean follow-up, compared with less intensive BP treatment, 
more intensive BP treatment lowered major cardiovascular 
events 14%, myocardial infarction 13%, stroke 22%, 
albuminuria 10%, and retinopathy progression 19% (11). 
A meta-analysis of 123 antihypertensive drug trials 
including 613,815 participants demonstrated that every 
10 mmHg decreases in SBP lowered major cardiovascular 
disease events 20%, coronary heart disease 17%, stroke 27%, 
heart failure 28%, and all-cause mortality 13% (12).
The Heart Outcomes Prevention Evaluation (HOPE)-3 
trial randomized 12,705 participants at intermediate risk 
who did not have cardiovascular disease with a mean BP 
of 138.1/81.9 mmHg to receive candesartan 16 mg daily 
plus hydrochlorothiazide 12.5 mg daily or placebo (13). 
The decrease in BP was 6.0/3.0 mmHg greater in the BP 
treatment group than in the placebo group. Median 
follow-up was 5.6 years. The first coprimary endpoint of 
a composite of cardiovascular death, nonfatal myocardial 
infarction, or nonfatal stroke was insignificantly lowered 7% 
by drug treatment (13). The second coprimary endpoint 
additionally included resuscitated cardiac arrest, heart 
failure, and revascularization and was insignificantly lowered 
5% by drug treatment. Participants in the upper third of 
SBP (>143.5 mmHg) had a significant reduction in the first 
coprimary endpoint of 23% and in the second coprimary 
endpoint of 28% if they were treated with candesartan plus 
hydrochlorothiazide (13). Reasons for the difference in 
results between the SPRINT trial and the HOPE-3 trial are 
discussed by their investigators (14,15).
The National Heart Foundation of Australia 2016 
guideline for management of hypertension recommends 
ambulatory and/or home BP monitoring if the clinic BP 
is ≥140/90 mmHg as out-of-clinic BP is a stronger 
predictor of outcome (16). This guideline also recommends 
in selected high cardiovascular risk populations a SBP goal 
of <120 mmHg to improve cardiovascular outcomes. Close 
follow-up is recommended in these persons to identify 
treatment-related adverse effects including hypotension, 
syncope, electrolyte abnormalities, and acute kidney injury (16). 
The 2016 Canadian hypertension guideline recommends 
for high-risk patients aged 50 years and older with SBP 
levels of 130 mmHg and higher intensive BP management 
to target a SBP goal of 120 mmHg and lower (17). Intensive 
BP management should be guided by automated office 
BP measurements. Clinical indications defining high-risk 
patients for consideration for intensive BP treatment are 
clinical or subclinical cardiovascular disease or chronic kidney 
disease (nondiabetic nephropathy, proteinuria <1 gram/day, 
estimated glomerular filtration rate 20–59 mL/min per 1.73 m2) 
or estimated 10-year global cardiovascular risk ≥15% or 
age ≥75 years (17). Persons with 1 or more of these clinical 
indications should consent to intensive BP treatment (17). 
At 24-year median follow-up of the Trials of Hypertension 
Prevention, in which 744 phase I and 2,382 phase II persons 
were randomized to sodium reduction or control, there was 
an increased risk of all-cause mortality for high sodium 
intake and a direct relationship with all-cause mortality, 
even at the lowest levels of sodium intake (18). The hazard 
ratio per unit increase in sodium/potassium ratio was 1.13 (18).
Using data from a population-based 11-cohort 
International Database on Ambulatory Blood Pressure 
Monitoring in Relation to Cardiovascular Outcomes, 
a study compared daytime ambulatory blood pressure 
monitoring with conventional BP measurements in 653 
untreated adults with white coat hypertension and 653 
normotensive control adults (19). Median follow-up was 
10.6 years, This study showed that after accounting for 
age, the size of the white coat effect was not influenced 
by the severity of risk for cardiovascular disease or the 
presence of past cardiovascular disease events (19). The 
risk of cardiovascular disease in most adults with white 
coat hypertension was comparable to age-and risk-adjusted 
normotensive control persons (19).
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